ELYM News and Press, Eliem Therapeutics Inc From 03/11/24

Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...

Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Eliem Therapeutics Inc (ELYM) is expected to report for Q3 2023

2023-07-21 08:20:49 ET Colombier Acquisition ( PSQH ) -16% . Sirius XM Holdings ( SIRI ) -9% as analysts downgrade after 'massive' run . 60 Degrees Pharmaceuticals ( SXTP ) -9% . The Interpublic Group of Companies ( IPG ) -8% on reporting ...

SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further develo...

2023-05-11 17:46:02 ET Eliem Therapeutics press release ( NASDAQ: ELYM ): Q1 GAAP EPS of -$0.84. Cash, cash equivalents and marketable securities was $109.4 million as of March 31, 2023, as compared to $123.6 million as of December 31, 2022. The Company’s current ca...

Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, U...

2023-03-06 17:32:22 ET Eliem Therapeutics press release ( NASDAQ: ELYM ): Q4 GAAP EPS of -$0.29 beats by $0.04 . Cash, cash equivalents and marketable securities were $123.6 million as of December 31, 2022, compared to $161.4 million as of December 31, 2021. For ...

Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWS...